Efficacy of bolus and infusional 5-FU in elderly and non-elderly patients with metastatic colorectal cancer - a pooled analysis of clinical trials

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 8045-8045 ◽  
Author(s):  
G. Folprecht ◽  
D. Cunningham ◽  
B. Glimelius ◽  
F. Dicostanzo ◽  
J. Wils ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Clinical Trials ◽  
Elderly Patients ◽  
Metastatic Colorectal Cancer ◽  
Pooled Analysis

Efficacy of bolus and infusional 5-FU in elderly and non-elderly patients with metastatic colorectal cancer - a pooled analysis of clinical trials

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 8045-8045
Author(s):  
G. Folprecht ◽  
D. Cunningham ◽  
B. Glimelius ◽  
F. Dicostanzo ◽  
J. Wils ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Clinical Trials ◽  
Elderly Patients ◽  
Metastatic Colorectal Cancer ◽  
Pooled Analysis

scholarly journals Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials

2004 ◽  
Vol 15 (9) ◽  
pp. 1330-1338 ◽  
Author(s):  
G. Folprecht ◽  
D. Cunningham ◽  
P. Ross ◽  
B. Glimelius ◽  
F. Di Costanzo ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Clinical Trials ◽  
Elderly Patients ◽  
Metastatic Colorectal Cancer ◽  
Pooled Analysis

A Critical Review of Second-generation anti-EGFR Monoclonal Antibodies in Metastatic Colorectal Cancer

2020 ◽  
Vol 21 ◽  
Author(s):  
Daniel Sur ◽  
Andrei Havasi ◽  
Alecsandra Gorzo ◽  
Claudia Burz
Keyword(s):  
Colorectal Cancer ◽  
Drug Resistance ◽  
Clinical Trials ◽  
Monoclonal Antibodies ◽  
Metastatic Colorectal Cancer ◽  
Second Generation ◽  
Current Data ◽  
Braf Mutations ◽  
Durable Response ◽  
Ongoing Research

Background: Anti-EGFR monoclonal antibodies (mAbs) have become a relevant solution for the treatment of patients with metastatic colorectal cancer. Current anti-EGFR monoclonal antibodies face a series of problems, including resistance and non-durable response, and RAS and BRAF mutations serve as exclusion criteria for treatment with anti-EGFR mAbs. Advances in molecular tumor profiling and information on subsequent pathways responsible for disease progression and drug resistance helped develop a new generation of anti-EGFR mAbs. These second-generation mAbs have been developed to overcome existing resistance mechanisms and to limit common side effects. For the moment, existing literature suggests that these novel anti-EGFR mAbs are far from finding their way to clinical practice soon. Objective: In this review, we summarize and evaluate current data regarding ongoing research and completed clinical trials for different second-generation anti-EGFR monoclonal antibodies. Conclusion: Anti-EGFR mAbs exhibit efficacy in advanced colorectal cancer, but second-generation mAbs failed to prove their benefit in the treatment of metastatic colorectal cancer. Understanding the biological basis of primary and acquired drug resistance could allow scientists to design better clinical trials and develop improved second-generation mAbs.

Sign in / Sign up

Export Citation Format

Share Document